Dow closes higher as oil tumbles, Nasdaq slips with Nvidia leading chip selloff

Nvidia shares dropped more than 4% and the Nasdaq 100 fell after a 3% drop in Nvidia, driving chip-sector weakness.

Choppy to downside bias for NVDA and AI-semi peers into the next earnings and macro catalysts.

The article attributes the tech selloff to NVDA’s same-day decline, but provides no new NVDA-specific fundamental datapoint beyond the WSJ OpenAI data-center talk.

ASML fell more than 5% after The Information said a Chinese state-backed firm began mass-producing critical chipmaking equipment.

Further volatility risk if the China DUV mass-production story gains traction.

The article directly links ASML’s intraday drop to China mass-producing DUV lithography machines and concerns about older-generation tool sales.

AMD shares fell about 7.3% by midday alongside ASML and Micron after reports of China mass-producing domestic DUV lithography machines.

Downside bias versus the broader market until the sector narrative stabilizes.

The move is described as read-through from the DUV/ASML competition report rather than an AMD-specific catalyst.

Micron Technology shares were down nearly 5% by midday as China’s domestic DUV lithography progress raised competition concerns.

Likely to remain correlated with semi sentiment through the week’s earnings and Fed decision.

The article frames MU’s decline as part of the broader chip selloff tied to the DUV story.

Medicus Pharma received FDA authorization to begin its Phase 2b registrational study of SkinJect for Gorlin syndrome.

Potential upside reaction and higher probability of follow-on catalysts around trial progress.

The article provides a specific FDA authorization event, but no trial results or guidance on timelines beyond starting the study.

Forte Biosciences jumped after argenx agreed to acquire it for about $2.2 billion at $77 per share in cash.

Support from deal arbitrage dynamics; upside capped by deal risk until closing certainty improves.

The article discloses the acquisition agreement, price per share, and cash consideration, which are primary deal-trading inputs.

SpaceX shares dropped to a record low as investors weighed concerns about an upcoming share lock-up expiration and financing needs.

Near-term downside or elevated volatility until lock-up/financing details are clarified.

The article cites specific investor concerns, but does not provide new lock-up terms or financing amounts.

Capricor Therapeutics plunged after FDA reviewers raised concerns about deramiocel effectiveness ahead of an advisory committee review.

High volatility with downside risk into the advisory committee outcome.

The article ties the selloff to FDA reviewer concerns and an upcoming advisory committee, a direct catalyst.